Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional ...

AnaptysBio, Inc. (ANAB) shares rallied 9.5% in the last trading session to close at $18.71. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Investing.com -- Shares of AnaptysBio (NASDAQ:ANAB) climbed 12% today as the company announced a significant stock repurchase plan, signaling confidence in its financial position and future prospects.

In a report released on April 1, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

The firm keeps a Buy rating on AnaptysBio shares. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on ...

ANAB opened at $18.44 on Wednesday. AnaptysBio has a 12 month low of $12.21 and a 12 month high of $41.31. The business’s 50-day moving average price is $16.95 and its 200-day moving average ...

(RTTNews) - AnaptysBio, Inc. (ANAB) on Monday announced that its Board of Directors has authorized a stock repurchase plan under which the company may repurchase up to $75 million of its ...

U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Monday. Shares of Intuitive Machines, Inc. LUNR rose sharply during Monday's session following fourth-quarter results ...

Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies ...

Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking the stock’s steepest single-day loss since March 2021. The collapse ...